NeuroOne Medical Technologies Amends Corporate Documents
Ticker: NMTC · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, amendment, bylaws
TL;DR
NeuroOne Medical just changed its bylaws and articles of incorporation, effective today. Check the details.
AI Summary
On June 20, 2024, NeuroOne Medical Technologies Corporation filed an 8-K report detailing amendments to its Articles of Incorporation. These changes, effective June 20, 2024, involve material modifications to the rights of security holders and amendments to its bylaws. The filing also includes financial statements and exhibits related to these corporate actions.
Why It Matters
This filing indicates significant corporate governance changes that could impact shareholder rights and the company's operational structure.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance updates and amendments, not a significant event like a merger or financial distress.
Key Players & Entities
- NeuroOne Medical Technologies Corporation (company) — Registrant
- June 20, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of incorporation
- Eden Prairie, MN (location) — Principal executive address
FAQ
What specific rights of security holders were modified by the amendments?
The filing indicates material modifications to the rights of security holders but does not specify the exact nature of these modifications in the provided text.
What are the key changes in the amendments to the Articles of Incorporation or Bylaws?
The filing states that amendments were made to the Articles of Incorporation or Bylaws, but the specific details of these changes are not provided in this excerpt.
When were these amendments to the corporate documents effective?
The amendments were effective as of June 20, 2024.
What is the primary purpose of filing this 8-K report?
The primary purpose is to report material modifications to the rights of security holders and amendments to the company's Articles of Incorporation or Bylaws.
Does this filing include any new financial statements?
Yes, the filing indicates that financial statements and exhibits are included as part of this report.
Filing Stats: 837 words · 3 min read · ~3 pages · Grade level 14.2 · Accepted 2024-06-21 16:15:41
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
Filing Documents
- ea0208217-8k_neuro.htm (8-K) — 30KB
- ea020821701ex3-1_neuro.htm (EX-3.1) — 157KB
- 0001213900-24-054782.txt ( ) — 396KB
- nmtc-20240620.xsd (EX-101.SCH) — 3KB
- nmtc-20240620_lab.xml (EX-101.LAB) — 33KB
- nmtc-20240620_pre.xml (EX-101.PRE) — 22KB
- ea0208217-8k_neuro_htm.xml (XML) — 4KB
03 Material Modification to Rights of Security Holders
Item 3.03 Material Modification to Rights of Security Holders. To the extent applicable, the information set forth under Item 5.03 below is incorporated by reference as if fully set forth herein.
03 Amendments to Articles of Incorporation or Bylaws; Change
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 20, 2024, the Board of Directors (the " Board ") of NeuroOne Medical Technologies Corporation (the " Company ") approved and adopted the Company's Amended and Restated Bylaws (the " Amended and Restated Bylaws "), which became effective the same day. Among other things, the amendments contained in the Amended and Restated Bylaws: Reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the voting power of the outstanding shares of stock entitled to vote to one-third of the voting power of the outstanding shares of stock entitled to vote. Address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by providing that no person may solicit proxies in support of a director nominee other than the Board's nominees unless such person has, or is part of a group that has, complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the " Exchange Act "), including applicable notice and solicitation requirements. Update disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company's proxy materials pursuant to Rule 14a-8 under the Exchange Act), including, without limitation, disclosure of derivative security interests and material interests, agreements and relationships between a proposing stockholder (and other participants in a solicitation) and the Company as well as between proposed director nominees and a proposing stockholder and providing that the Board may request a proposing stockholder or proposed director nominee to provide additional information as reasonably required by the Board. Require a stockholder or group of stockholders calling a special meeting in order to nominate a person to the Board to hold 10% of the votes at the meet
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation 104 Cover Page Interactive Data File (embedded with Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: June 21, 2024 By: /s/ David Rosa David Rosa Chief Executive Officer 2